Most Read Articles
Stephen Padilla, 6 days ago
Early administration of recombinant human B-type natriuretic peptide (rhBNP) can lower the incidence of reperfusion injury for patients with ST-elevation myocardial infarction (STEMI) who are receiving percutaneous coronary intervention (PCI) treatment, according to a China study.
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
3 days ago
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.
2 days ago
Systolic blood pressure appears to have a strong association with aneurysmal subarachnoid haemorrhage (aSAH) but not with unruptured intracranial aneurysm (UIA), whereas current smoking and female sex are risk factors for both conditions, a study has found.

Venous thromboembolism incidence similar in obese, nonobese patients taking enoxaparin

11 May 2019

No statistically significant difference exists in venous thromboembolism incidence between obese, overweight and nonobese hospitalized patients receiving approved enoxaparin prophylaxis doses, reports a recent study.

A total of 428 patients were included, of which eight (1.9 percent) had venous thromboembolism (three in the nonobese group; two in the overweight group; three in the obese group). There were no statistically significant differences found between the three groups (p=0.81).

Differences were also not statistically significant between overweight (odds ratio [OR], 0.685; 95 percent CI, 0.115–4.095), obese (OR, 0.797; 0.353–1.796), and combined overweight and obese (OR, 0.656; 0.154–2.799) groups compared to patients with normal body weight when incidence of venous thromboembolism was adjusted for age and sex.

This retrospective cohort study compared the incidence of venous thromboembolism between obese and nonobese hospitalized patients who received prophylactic enoxaparin doses and described enoxaparin dosing strategies used in obese patients.

Participants included those who were admitted to Parkview Regional Medical Center, Parkview Hospital or Parkview Orthopedic Hospital between September 2011 and August 2012 and received at least one dose of 30-mg enoxaparin twice daily or 40-mg enoxaparin once daily for venous thromboembolism prophylaxis.

Patients were classified into three groups based on their body mass index (BMI): group 1 (nonobese: BMI <25 kg/m2), group 2 (overweight: BMI ≥25 kg/m2 but <30 kg/m2) and group 3 (obese: BMI ≥30 kg/m2). Venous thromboembolism occurrence within 90 days, considering day 1 of hospitalization as day 1, was the primary endpoint.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 6 days ago
Early administration of recombinant human B-type natriuretic peptide (rhBNP) can lower the incidence of reperfusion injury for patients with ST-elevation myocardial infarction (STEMI) who are receiving percutaneous coronary intervention (PCI) treatment, according to a China study.
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
3 days ago
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.
2 days ago
Systolic blood pressure appears to have a strong association with aneurysmal subarachnoid haemorrhage (aSAH) but not with unruptured intracranial aneurysm (UIA), whereas current smoking and female sex are risk factors for both conditions, a study has found.